Evotec Reports Third Quarter and Nine-Month 2026 Results: Building Growth Momentum Toward 2030 Goals

Evotec posts weak Q3 profit, reaffirms 2026 outlook, but long-term targets remain aspirational.

What the company is saying

Evotec SE presents its Q3 and nine-month 2026 results as evidence of operational progress and strategic momentum, highlighting €164.9 million in Q3 revenue and €465.0 million for the nine months. The company emphasizes a 24% year-on-year increase in net sales for its Discovery & Preclinical Development (D&PD) base business and stresses the delivery of over 20% of its €75 million annual run-rate savings target by September. Management, led by CEO Dr. Christian Wojczewski and newly appointed Chief Scientific Officer Dr. Joanna Holbrook, frames the narrative around transformation, cost discipline, and new commercial partnerships, including deals with Vertex Pharmaceuticals, Plectonic, and Odyssey Therapeutics. The announcement reaffirms full-year 2026 guidance and details a 2030 framework targeting €1 billion in revenue and a 20%+ EBITDA margin, though these are positioned as medium- to long-term ambitions. The tone is confident, with management attributing improved EBITDA to lower costs and operational efficiencies, but the company acknowledges ongoing strategic review and transformation efforts.

What the data suggests

The disclosed figures show Q3 2026 group revenue of €164.9 million, essentially flat versus the prior-year quarter (€163.9 million), and nine-month revenue of €465.0 million, down 13.1% from €535.1 million in 2025. Adjusted Group EBITDA for Q3 improved to -€1.6 million, an 89.1% year-on-year improvement, but remains negative. For the nine months, adjusted EBITDA worsened to -€44.3 million from -€16.9 million prior-year. D&PD segment revenue declined 11.2% year-on-year for the nine months, while Just – Evotec Biologics (JEB) revenue fell 18.3%, primarily due to the absence of a $25 million Sandoz license sale and delayed programs. R&D expenses dropped to €29.7 million (6.4% of revenue) from €42.3 million (7.9%), reflecting cost-cutting. Liquidity stands at €400.9 million, but the company is in a net debt position. While cost savings are materializing, revenue and profitability trends are negative, and the 2030 targets are projections without interim milestones or binding contracts.

Analysis

The announcement is upbeat, emphasizing operational progress, cost savings, and ambitious long-term targets. However, the majority of the positive narrative is forward-looking: the 2030 revenue and margin framework, segment contribution projections, and expectations of improved profitability are all aspirational and not yet realized. While the company discloses detailed revenue and EBITDA figures, these remain negative, and both D&PD and JEB segments show year-on-year revenue declines for the nine-month period. The cost-saving progress is partial (over 20% of the €75m target delivered), but the transformation program and strategic review are ongoing, with full benefits not expected until 2027 or later. The capital intensity flag is triggered by the scale of the transformation and growth ambitions, paired with only long-dated, uncertain returns. The gap between narrative and evidence is most pronounced in the 2030 framework and segment contribution forecasts, which are not supported by interim milestones or binding contracts.

Risk flags

• ●Revenue and profitability are deteriorating year-on-year, with nine-month group revenue down 13.1% and adjusted EBITDA worsening to -€44.3 million, raising concerns about the sustainability of the business if trends persist.
• ●The 2030 revenue and margin targets are highly aspirational, with no disclosed interim milestones, binding contracts, or evidence that current operational improvements will scale to the projected levels.
• ●Cost savings from the Horizon transformation are only partially realized, with more than 20% of the €75 million target delivered by September, but the remainder requires continued execution and may face operational challenges.
• ●Segment performance is uneven: D&PD and JEB both posted significant year-on-year revenue declines for the nine months, and JEB's prior-year results were boosted by a one-off $25 million license sale, masking underlying weakness.
• ●Liquidity is reported at €400.9 million, but the company is in a net debt position, which could constrain flexibility if operational improvements do not materialize or if further investment is required to achieve long-term targets.

Bottom line

Evotec's Q3 and nine-month 2026 results reveal flat quarterly revenue and worsening profitability, with both core segments posting year-on-year declines for the nine months. Management's narrative focuses on cost savings, operational progress, and new collaborations, but the most substantial improvements remain in the future. The reaffirmed 2026 guidance and partial delivery of cost savings provide some near-term stability, yet the €1 billion revenue and 20%+ EBITDA margin targets for 2030 are long-dated and lack supporting detail or interim milestones. Investors should treat the 2030 framework as aspirational, not as a base case, until more concrete evidence of revenue growth and sustained profitability emerges. The most important takeaway is that while operational discipline is improving, the company remains in a loss-making position and must deliver on execution to justify its long-term ambitions.

Announcement summary

(NASDAQ:EVO) Evotec SE announced its financial results for the third quarter and first nine months of 2026, provided updates on its Horizon transformation program, and outlined its strategic and financial ambitions for 2030. Group revenue for Q3 2026 was €164.9 million, with nine-month revenue at €465.0 million; at constant exchange rates (CER), these were €164.2 million and €477.4 million, respectively. Adjusted Group EBITDA was -€1.6 million for Q3 and -€44.3 million for the nine months, with CER figures at -€1.7 million and -€39.1 million. Net sales in the Discovery & Preclinical Development (D&PD) base business increased 24% year-on-year for the first nine months. The company reaffirmed its full-year 2026 guidance, expecting Group revenue of €570 to €610 million (€595 to €635 million CER) and adjusted Group EBITDA of -€105 to -€70 million (-€90 to -€60 million CER). The 2030 framework targets around €1 billion in Group revenue by 2030, with an adjusted EBITDA margin of 20% at year-end 2028 and above 20% at year-end 2030. By September, Evotec had delivered more than 20% of its €75 million annual run-rate savings target, already within the 20-30% contribution planned for full-year 2026. The D&PD base business is expected to contribute approximately 40% of Group revenue in 2030, with D&PD strategic partnerships and innovation-related activities contributing about 20% at above-average margins, and Just – Evotec Biologics (JEB) expected to contribute about 40%. In Q3 2026, D&PD revenue was €120.1 million (€119.6 million CER), a 2.3% year-on-year decline, and adjusted EBITDA improved to -€1.0 million (-€1.4 million CER). For the first nine months, D&PD revenue was €348.0 million (€355.5 million CER), down 11.2% year-on-year, with adjusted EBITDA at -€25.5 million (-€19.8 million CER). JEB revenue for Q3 2026 was €44.8 million (€44.6 million CER), a 9.4% increase year-on-year, with adjusted EBITDA at -€0.6 million (-€0.3 million CER). For the nine months, JEB revenue was €117.1 million (€121.9 million CER), down 18.3% year-on-year, mainly due to the $25 million Sandoz license sale recognized in Q1 2025 and delayed program activities; adjusted EBITDA was -€18.8 million (-€19.3 million CER). R&D expenses for the nine months were €29.7 million or 6.4% of total Group revenue, compared to €42.3 million or 7.9% in the prior-year period. The company ended Q3 2026 with a liquidity position of €400.9 million. Recent business highlights include selection by Vertex Pharmaceuticals for commercial manufacturing of povetacicept, advancement of the orthopoxvirus antibody program into Phase 1 with the U.S. Department of War, and new collaborations with Plectonic and Odyssey Therapeutics. Dr. Joanna Holbrook was appointed Chief Scientific Officer effective November 1, 2026, succeeding Dr. Cord Dohrmann. The strategic review announced in May 2026 remains ongoing alongside the Horizon transformation program.

Disagree with this article?